Will Dogwood Therapeutics stock go up?

According to Danelfin AI, Dogwood Therapeutics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (49.20%) is -1.62% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Dogwood Therapeutics stock?

The Dogwood Therapeutics target price is $12.44 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Dogwood Therapeutics stock right now?

Dogwood Therapeutics has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (49.20%) is -1.62% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Dogwood Therapeutics stock is a good buy .

Is Dogwood Therapeutics undervalued right now?

Based on analysts, the average price target upside for Dogwood Therapeutics is +718.18% (1Y). According to Danelfin AI, Dogwood Therapeutics has today an AI Score of 4/10 (Hold Rating).

What was the price range of Dogwood Therapeutics stock over the past 12 months?

The Dogwood Therapeutics stock price range over the past 12 months has been $1.34 - $7.91.

What is going on with Dogwood Therapeutics stock in the last 3 months?

The Dogwood Therapeutics stock performance in the last quarter has been -27.96%.

Does Dogwood Therapeutics offer dividend payments?

No, Dogwood Therapeutics does not currently pay dividends.

What is the current market capitalization of Dogwood Therapeutics?

Dogwood Therapeutics's market cap is $50.44M, as of 2026-07-02 08:00.

When is the next DWTX earnings report date?

DWTX will publish its next earnings report on 2026-05-14.

Dogwood Therapeutics Inc (DWTX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

DWTX AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Dogwood Therapeutics Inc today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 49% probability of outperforming the market in the next 3 months, which is 2% lower than the average probability of any stock (51%). Among the top positive contributors, the Fear & Greed Index (CNN) (value: 31) boosts the probability by +2.59%, the Fundamentals Impact (Long Tail) adds +1.93%, and the Beginning Cash (Millions) (value: $6.52M, bottom 20%) contributes +1.86%. Additionally, Maximum Volatility (value: 10.23, top 20%) adds +1.71%, the Biotechnology industry adds +1.20%, and Tangible Shareholders' Equity (value: $0.60M, bottom 30%) adds +1.07%. On the detractor side, the Technicals Impact (Long Tail) reduces probability by -8.87%, the Chart Pattern (180d) (cluster_21) detracts -3.26%, Alpha Last Day (value: -5.46%, bottom 10%) detracts -1.74%, ATR (14d Volatility) (value: 0.15, bottom 20%) detracts -1.14%, Short Float (%) (value: 31%, bottom 10%) detracts -0.94%, and Distance from KAMA (20d) (value: -4.23%, bottom 40%) detracts -0.77%. Notable data points include the Normalized Average True Range (100d) in the top 10% (value: 20.48), indicating extremely high long-term volatility, which positively influences the probability. Conversely, Alpha Last Day and Short Float (%) are both in the bottom 10%, reflecting recent underperformance and high bearish sentiment. The Fear & Greed Index at 31 suggests fear in the market, which historically can be a contrarian positive. Overall, the stock's probability is weighed down by negative technical and short-term factors, but supported by high volatility and fundamental signals, resulting in a Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Volatility+4.03%
How much the stock price tends to fluctuate
Valuation+3.75%
How the stock is priced relative to its fundamentals
Sentiment+2.77%
How analysts and the market view the stock
Size & Liquidity+1.86%
Company size and trading liquidity
Earnings Quality+0.53%
Stability and reliability of reported earnings

Momentum-14.57%
Direction and strength of recent price movements

DWTX probability advantage of beating the market (3M):

-1.62%

AI Score

Hold

Dogwood Therapeutics (DWTX) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -1.62% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of DWTX (49.20%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
DWTX probability advantage of beating the market (3M)-1.62%
DWTX probability of beating the market (3M)49.20%

DWTX probability advantage of beating the market (3M): -1.62%

The AI-powered overall analysis of Dogwood Therapeutics (DWTX) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of DWTX:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Technicals Impact (Long Tail)	-	N/A	-8.87%
Technical	Chart Pattern (180d)	figure_21	N/A	-3.26%
Sentiment	Fear & Greed Index (CNN)	31	N/A	+2.59%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.93%
Fundamental	Beginning Cash (Millions)	6.52		+1.86%
Technical	Alpha Last Day	-0.05%	N/A	-1.74%
Technical	Maximum Volatility	10.23%		+1.71%
Sentiment	Industry (GICS)	Biotechnology	N/A	+1.20%
Technical	ATR (14d Volatility)	0.15		-1.14%
Fundamental	Tangible Shareholders' Equity	0.6		+1.07%
Technical	Upgrade to unlock			+1.03%
Technical	Upgrade to unlock			+0.99%
Sentiment	Upgrade to unlock			-0.94%
Technical	Upgrade to unlock			+0.85%
Technical	Upgrade to unlock			+0.78%

Rest of Alpha Signals: +0.29%

DWTX probability advantage of beating the market (3M)Total:-1.62%
DWTX AI Score

Significant changes Vs previous day

DWTX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.52
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

DWTX Proven Hold Signal & Price Forecast

This is the price chart for DWTX from January 1, 2026 until today. The chart indicates, in yellow, the 40 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

DWTX Average Past Performance & Win Rate

Three months after its 86 Hold signals since July 2026, DWTX had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

86 Past DWTX Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Win Rate (% Positive Perf.)				0.00%
% Positive Alpha				0.00%

DWTX Frequently Asked Questions

Will Dogwood Therapeutics stock go up?
According to Danelfin AI, Dogwood Therapeutics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (49.20%) is -1.62% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Dogwood Therapeutics stock?
Is it a good time to buy, sell, or hold Dogwood Therapeutics stock right now?
Is Dogwood Therapeutics undervalued right now?
What was the price range of Dogwood Therapeutics stock over the past 12 months?
What is going on with Dogwood Therapeutics stock in the last 3 months?
Does Dogwood Therapeutics offer dividend payments?
What is the current market capitalization of Dogwood Therapeutics?
When is the next DWTX earnings report date?

Dogwood Therapeutics Inc Company Profile

Dogwood Therapeutics Inc (DWTX) discovers, develops, and commercializes biopharmaceutical products. It provides therapeutic options for patients with complex and severe diseases. The company's work spans drug discovery, clinical development, and market introduction. Its scientific approach integrates biological insights with technological platforms to address medical challenges.

The company maintains a research and development pipeline. This pipeline targets several therapeutic areas, including oncology, immunology, and neurological disorders. Dogwood Therapeutics identifies and validates novel drug targets. Its discovery efforts encompass small molecule compounds and complex biologic therapies. These include monoclonal antibodies, gene therapies, and cell-based treatments.

Dogwood Therapeutics manages clinical development programs. These programs assess the safety and efficacy of investigational medicines. They span all phases of clinical trials. The company collaborates with academic institutions and clinical research organizations. It also navigates global regulatory pathways to secure approvals for new treatments. The company then commercializes its approved products.

This commercialization includes manufacturing, supply chain management, and market access strategies. Dogwood Therapeutics ensures its medicines reach patients and healthcare systems. It also engages in post-market surveillance and pharmacovigilance for its portfolio. The company continuously monitors product performance and patient safety.

Dogwood Therapeutics primarily serves patients, healthcare professionals, and medical institutions. Its products are distributed through direct sales forces and alliances with pharmaceutical and biotechnology partners. Revenue is generated from product sales and licensing agreements, with recurring elements from ongoing collaborations and milestone payments, distributed through direct and channel partners to a global market.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:44 Milton Avenue, Alpharetta
Employees:8
Website:dwtx.com

Pros

High switching costs for established therapies

Patent exclusivity for novel drug compounds

Pricing power for innovative medical solutions

Recurring revenue from chronic disease treatments

Regulatory barriers to market entry

Cons

High capital intensity of drug development

Long development cycles for new therapies

Clinical trial failure and regulatory approval risk

Patent expiration leading to generic competition

Reimbursement pressure from payers

Company	AI Score	Compare
CADLCandel Therapeutics Inc
DNLIDenali Therapeutics Inc
NTHINeOnc Technologies Holdings Inc
CYCNCyclerion Therapeutics Inc
TNXPTonix Pharmaceuticals Holding Corp

Company	AI Score	Compare
CADLCandel Therapeutics Inc
DNLIDenali Therapeutics Inc
NTHINeOnc Technologies Holdings Inc
CYCNCyclerion Therapeutics Inc
TNXPTonix Pharmaceuticals Holding Corp

DWTX Stock AI Analysis High Risk